Gilbert Cisneros Buys Shares of Novanta Inc. (NASDAQ: NOVT)

U.S. House member Gilbert Cisneros disclosed a purchase of Novanta Inc. shares valued between $1,001 and $15,000.

Written by Trueearnings · Published Jun 13, 2026, 2:09 AM EDT · Updated Jun 14, 2026, 8:01 PM EDT

Key Points

Gilbert Cisneros, a member of the U.S. House, bought Novanta Inc. shares valued between $1,001 and $15,000 on May 18, 2026.
Novanta Inc. trades on the NasdaqGS under the ticker NOVT, with a market cap of approximately $5.72 billion and a forward P/E ratio of 38.74.
Recent insider activity includes CEO Matthijs Glastra selling shares, while analysts maintain a strong buy consensus with a mean price target of $175.

Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical

All-time return -1.0% S&P 500 +93.0%

vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

U.S. House member Gilbert Cisneros recently disclosed a purchase of shares in Novanta Inc. (NASDAQ: NOVT), valued between $1,001 and $15,000. This transaction was reported on June 9, 2026, but took place on May 18, 2026. Cisneros's move reflects a personal investment in the technology sector, specifically in a company known for its precision medicine and manufacturing solutions.

Other Institutional Activity in Novanta Inc.

BlackRock, Inc. grew its holdings in Novanta by 74,166 shares, bringing its total to approximately 4.65 million shares, valued at about $549.8 million. Vanguard Portfolio Management LLC entered a new position with 2.48 million shares, worth roughly $292.5 million. Price T Rowe Associates Inc. added 1,175,998 shares, increasing its stake by 193.3% to 1.78 million shares, valued at $210.8 million. Allspring Global Investments Holdings, LLC also increased its position, adding 377,232 shares to reach a total of 1.78 million shares, valued at $210.3 million.

Novanta Inc. Stock Snapshot

Shares of Novanta Inc. (NASDAQ: NOVT) are trading near $162.41. The company has a market cap of approximately $5.72 billion and a forward P/E ratio of 38.74. With a beta of 1.683, the stock shows a 52-week range between $98.27 and $171.85. The 50-day moving average is $142.65, while the 200-day moving average is $126.17. Novanta maintains a current ratio of 3.564 and a quick ratio of 2.549, with a debt-to-equity ratio of 22.222.

Recent Earnings

In its latest earnings report, Novanta Inc. recorded revenue of approximately $1.00 billion, reflecting a growth of 10.4%. The company's net margin stood at 5.35%, with a return on equity (ROE) of 5.16%. Earnings per share (EPS) were $1.40. The company announced its next earnings date for May 11, 2026.

Insider Buying and Selling at Novanta Inc.

CEO Matthijs Glastra executed several planned sales, including 6,500 shares on June 2, 2026, at an average price of $168.66, and 7,500 shares on May 12, 2026, at $150.43. CFO Robert Buckley bought 9,957 shares on March 16, 2026, without a planned sale, at a price of $14.13, and sold the same amount at $116.77 under a planned transaction.

Analysts Set New Price Targets

On May 13, 2026, Baird maintained its buy rating for Novanta with a price target of $173. The consensus among analysts is a strong buy, with an average target price of $175, based on two analyst opinions.

About Novanta Inc.

Novanta Inc. specializes in precision medicine and manufacturing solutions, providing advanced technology for medical and industrial applications. The company, headquartered in Bedford, Massachusetts, operates through its Automation Enabling Technologies and Medical Solutions segments. Led by CEO Matthijs Glastra, Novanta employs around 3,000 people and focuses on sectors like robotics, laser solutions, and medical technology.

Bottom Line

Gilbert Cisneros's recent purchase of Novanta Inc. shares highlights the interest in the company's technology-focused offerings. Investors often track such trades for insights, though these disclosures are backward-looking. As Novanta continues to develop its precision solutions, it remains a company of interest in the tech sector.